Multiple Sclerosis (MS) Drug Market

RECENT NEWS
FiercePharma  Aug 17  Comment 
After taking a strong interest in drug prices over the last two years, Congress has been somewhat quieter on the topic over the summer. That changed on Thursday as Reps. Elijah Cummings and Peter Welch announced a new probe into multiple sclerosis...
MarketWatch  Aug 17  Comment 
Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) said Thursday morning that they are launching an investigation into multiple sclerosis drug prices, and have sent letters to seven pharmaceutical companies about their pricing strategies....
MedPage Today  Aug 15  Comment 
(MedPage Today) -- Jacqueline Nicholas, MD, MPH, on why so many MS patients give up injectables in the long run
NPR  Jul 14  Comment 
The innovative drug Ocrevus looks as if it could be a game-changer for people with MS. But it's very, very expensive. And as with any new medication, the long-term safety risks are unknown.
Mondo Visione  Jul 4  Comment 
The October Club, a committee of philanthropists based in the City, officially launched its partnership with its chosen annual charity, Multiple Sclerosis (MS) Trust, at the House of Commons yesterday. The event was hosted by Baroness Wheatcroft,...
FiercePharma  Jun 22  Comment 
The medical world has found no causal relationship between hepatitis B vaccine and nervous system diseases such as multiple sclerosis, but the Court of Justice of the European Union just rendered such scientific evidence unnecessary in confirming...
Motley Fool  Jun 8  Comment 
The threat of increasing competition for GW Pharmaceuticals' promising epilepsy drug took a toll on investors' confidence last month.
FierceBiotech  May 26  Comment 
Missing a secondary endpoint in the RADIANCE trial won't hinder the launch or commercial success of ozanimod, CFO Peter Kellogg tells Barclays analysts.
FiercePharma  May 24  Comment 
Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML.




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki